Cardio-oncology is an emerging discipline focused on the comprehensive management of patients with coexisting cancer and cardiovascular disease, aiming to optimize treatment and manage cardiotoxicity.
Answers are grounded in this paper and cite their sources.
Promotes integrated cardio-oncology care models; leaves open prospective trials to standardize cardiotoxicity prevention.
Due to the increasing number of long-term cancer survivors, the ageing of the population, as well as the increased incidence and prevalence of oncologic and cardiovascular diseases, the number of patients presenting oncologic and cardiologic co-morbidities are increasing. Accordingly, there is a rapidly growing need for a comprehensive and proficient management of patients in whom the two co-morbidities exist, and for cancer patients whose clinical history and oncologic treatment put them at higher risk for developing cardiovascular problems, in order to provide the optimal treatment in every situation, and to avoid the possibility that the development of the second disease does not lead to a reduction of therapeutic opportunities for the patient. A new discipline, cardio-oncology, has been created to deal with this need. Its aim is to investigate new strategies, collect new evidence-based indications and develop interdisciplinary expertise in order to manage this growing category of patients. Cardio-oncology deals with the following main clinical and research areas: early diagnosis of cardiotoxicity, risk stratification and preventions, treatment and monitoring of cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Daniela Cardinale (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: